Janney Montgomery Scott LLC grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 30.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 66,487 shares of the company's stock after purchasing an additional 15,332 shares during the period. Janney Montgomery Scott LLC's holdings in Cellebrite DI were worth $1,465,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its holdings in shares of Cellebrite DI by 136.3% in the third quarter. FMR LLC now owns 5,616,757 shares of the company's stock valued at $94,586,000 after purchasing an additional 3,239,307 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Cellebrite DI during the third quarter valued at approximately $23,402,000. Lord Abbett & CO. LLC purchased a new position in Cellebrite DI in the third quarter worth $11,523,000. Summit Partners Public Asset Management LLC bought a new position in Cellebrite DI in the 3rd quarter valued at $9,274,000. Finally, Meitav Investment House Ltd. increased its position in shares of Cellebrite DI by 29.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock valued at $34,797,000 after purchasing an additional 473,293 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts have commented on CLBT shares. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Finally, Craig Hallum boosted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has an average rating of "Buy" and a consensus target price of $21.57.
Check Out Our Latest Stock Analysis on Cellebrite DI
Cellebrite DI Stock Performance
Cellebrite DI stock traded up $0.20 during midday trading on Friday, reaching $25.41. 2,173,997 shares of the stock were exchanged, compared to its average volume of 1,697,083. The firm has a market cap of $5.23 billion, a PE ratio of -16.39, a PEG ratio of 3.55 and a beta of 1.47. Cellebrite DI Ltd. has a 52 week low of $8.91 and a 52 week high of $26.30. The company's fifty day moving average is $22.21 and its 200-day moving average is $18.73.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million during the quarter, compared to analysts' expectations of $102.06 million. During the same period in the previous year, the business earned $0.09 earnings per share. The firm's revenue was up 27.0% on a year-over-year basis. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
